AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:SNSSSunesis Pharmaceuticals Stock Price, Forecast & News

$0.39
-0.03 (-6.77 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.39
Now: $0.39
$0.42
50-Day Range
$0.39
MA: $0.43
$0.50
52-Week Range
$0.20
Now: $0.39
$1.13
Volume1.24 million shs
Average Volume1.49 million shs
Market Capitalization$43.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Sunesis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.07 million
Book Value$0.09 per share

Profitability

Net Income$-23,330,000.00

Miscellaneous

Employees29
Market Cap$43.87 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

How has Sunesis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Sunesis Pharmaceuticals' stock was trading at $0.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SNSS shares have decreased by 37.5% and is now trading at $0.3938. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sunesis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Sunesis Pharmaceuticals.

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Sunesis Pharmaceuticals.

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The biopharmaceutical company earned $0.12 million during the quarter, compared to analysts' expectations of $0.15 million. View Sunesis Pharmaceuticals' earnings history.

What price target have analysts set for SNSS?

3 equities research analysts have issued 1 year price targets for Sunesis Pharmaceuticals' shares. Their forecasts range from $0.50 to $1.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $0.75 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View analysts' price targets for Sunesis Pharmaceuticals.

What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (5/13/2020)
  • 2. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.79, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.7%, and tax rate of 15% beginning in FY 2024." (6/17/2019)

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

News stories about SNSS stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sunesis Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutSunesis Pharmaceuticals.

Are investors shorting Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,110,000 shares, a drop of 13.3% from the April 30th total of 1,280,000 shares. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.1% of the company's shares are short sold. View Sunesis Pharmaceuticals' Current Options Chain.

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), QUALCOMM (QCOM), NVIDIA (NVDA), Amarin (AMRN), Exelixis (EXEL), Crispr Therapeutics (CRSP), Micron Technology (MU), Novavax (NVAX), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the following people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

Who are Sunesis Pharmaceuticals' major shareholders?

Sunesis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Corriente Advisors LLC (2.71%), BlackRock Inc. (2.06%), Wells Fargo & Company MN (0.68%), Sphera Funds Management LTD. (0.65%), Burrage Capital Management LLC (0.61%) and Raymond James Financial Services Advisors Inc. (0.09%). Company insiders that own Sunesis Pharmaceuticals stock include Aisling Capital Iv, Lp and William P Quinn. View institutional ownership trends for Sunesis Pharmaceuticals.

Which major investors are selling Sunesis Pharmaceuticals stock?

SNSS stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., and Wells Fargo & Company MN. View insider buying and selling activity for Sunesis Pharmaceuticals.

Which major investors are buying Sunesis Pharmaceuticals stock?

SNSS stock was acquired by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, BlackRock Inc., Burrage Capital Management LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Aisling Capital Iv, Lp, and William P Quinn. View insider buying and selling activity for Sunesis Pharmaceuticals.

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $0.39.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $43.87 million and generates $2.07 million in revenue each year. The biopharmaceutical company earns $-23,330,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.